Low-Dose Aspirin and Cancer Risk
Author Information
Author(s): Friis S, Sørensen H T, McLaughlin J K, Johnsen S P, Blot W J, Olsen J H
Primary Institution: Institute of Cancer Epidemiology, Danish Cancer Society
Hypothesis
Does the use of low-dose aspirin reduce the risk of colorectal and other cancers?
Conclusion
The study found no substantial evidence that low-dose aspirin reduces the risk of colorectal or other cancers.
Supporting Evidence
- Overall, 2381 cancer cases were observed compared to 2187 expected.
- The SIR for total cancer was 1.09, indicating a slight increase in cancer risk among aspirin users.
- No significant risk reductions were observed for colorectal or gastrointestinal cancers.
- Increased SIRs were found for kidney and brain cancers.
- 80% of subjects received two or more prescriptions for low-dose aspirin.
Takeaway
This study looked at people taking low-dose aspirin to see if it helps prevent cancer, but it didn't find strong evidence that it does.
Methodology
The study used prescription data from a population in North Jutland, Denmark, to analyze cancer incidence among low-dose aspirin users.
Potential Biases
Possible exposure misclassification due to reliance on prescription data and lack of adjustment for confounding factors like smoking.
Limitations
The study relied on prescription data without information on over-the-counter aspirin use or compliance, which may have affected the results.
Participant Demographics
The cohort consisted of 51% men and 49% women, with a mean age of 70 years at entry.
Statistical Information
P-Value
1.09
Confidence Interval
1.05–1.13
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website